NewGam

BIOLOGICAL4 trials

Sponsors

Octapharma

Conditions

Chronic Inflammatory Demyelinating Poly(Radiculo)NeuropathyPrimary Immunodeficiency DiseasePrimary Immunodeficiency DiseasesPrimary Thrombocytopenia

Phase 3

A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases

CompletedNCT01012323

OctapharmaPrimary Immunodeficiency Diseases

Start: 2010-01-31End: 2012-06-30Updated: 2017-03-16

High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)

CompletedNCT01313507

OctapharmaPrimary Immunodeficiency Disease

Start: 2011-05-31End: 2012-09-30Updated: 2017-03-29

Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia

CompletedNCT01349790

OctapharmaPrimary Thrombocytopenia

Start: 2011-10-31End: 2013-07-31Updated: 2017-06-07

Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy

CompletedNCT02638207

OctapharmaChronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy

Start: 2017-09-27End: 2019-09-05Updated: 2021-02-16

Related Papers

Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study.

2023-06-282 citations

Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy

Brain2021-11-1737 citations

Efficacy and safety of a new intravenous immunoglobulin (Panzyga<sup>®</sup>) in chronic immune thrombocytopenia

Transfusion Medicine2019-01-2714 citations